赛升药业：控股子公司拥有治疗流感类产品

Group 1 - The core viewpoint of the article is that Sai Sheng Pharmaceutical (300485.SZ) has a subsidiary that offers products for treating influenza, but these products contribute a small portion to the company's main business revenue [1] - The company emphasizes that the use of its influenza products must follow medical advice, indicating a focus on responsible usage [1] - Investors are advised to be aware of the investment risks associated with the limited revenue contribution from the influenza product line [1]